Phase I/II, open-label, dose escalating study of injectable RT 002 [botulinum toxin A] in patients with moderate to severe glabellar lines

Trial Profile

Phase I/II, open-label, dose escalating study of injectable RT 002 [botulinum toxin A] in patients with moderate to severe glabellar lines

Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Jan 2015

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Glabellar lines
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 May 2014 New trial record
    • 13 May 2014 Positive results from this study were reported in late April 2014, according to a Revance Therapeutics media release.
    • 21 Apr 2014 Results published in the Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top